Impact of lower vasopressor use on survival in patients with heart failure on ECMO

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between vasopressor exposure levels and outcomes in adults experiencing cardiogenic shock who are receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO). It will enroll 534 patients across multiple centers, categorizing them into high-dose and low-dose vasopressor groups based on their Vasoactive-Inotropic Score. The primary focus is to determine if reduced vasopressor use can decrease 30-day mortality rates. Secondary outcomes will assess hospital survival, mechanical ventilation duration, and complications related to ECMO support.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
* First-time ECMO initiation.
* Venoarterial ECMO (VA-ECMO) as the initial mode.

Exclusion Criteria:

* Age \<18 years.
* Severe pulmonary hypertension.
* Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).
* Severe missing data.

Where it's running

• Beijing Anzhen Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiaotong Hou, MD
• Email: xt.hou@ccmu.edu.cn
• Phone: 010-64456631

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prolonged nasogastric ketone infusion for decompensated heart failure

  This will test whether a continuous nasogastric infusion of a ketone (D‑beta‑hydroxybutyrate) can safely reach target blood levels in adults with severely reduced ejection fraction admitted for acute decompensated heart failure or cardiogenic shock.

  Recruiting Phase 4 Institute for Clinical and Experimental Medicine · Prague, Prague · NCT07527156

• Magenta Elevate™ device for cardiogenic shock

  This trial tries the Magenta Elevate™ device to see if it can safely support people with cardiogenic shock caused by left ventricular failure.

  Recruiting at 8 sites Magenta Medical Ltd. · Tbilisi and 7 other locations · NCT07293923

• Hemodynamic resuscitation with a Swan-Ganz catheter in cardiogenic shock.

  This will try using a Swan‑Ganz (pulmonary artery) catheter to guide medicines and fluids in adults who have cardiogenic shock after a heart attack.

  Recruiting Bach Mai Hospital · Hanoi · NCT07062744

• Initiation and Titration of GDMT with Impella 5.5 in Heart Failure with Cardiogenic Shock

  This study tests a device-plus-drug strategy using the Impella 5.5 alongside optimized guideline-directed medical therapy to see if heart recovery improves in adults with decompensated heart failure and cardiogenic shock.

  Recruiting at 2 sites Abiomed Inc. · Tampa, Florida and 16 other locations · NCT06965504

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Assessing muscle thickness changes in heart failure patients

  This study is testing how muscle thickness changes in heart failure patients receiving advanced treatments like heart transplants or assist devices to see how it affects their recovery.

  Recruiting Tufts Medical Center · Boston, Massachusetts · NCT06253104

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.